An NCI-designated Comprehensive Cancer Center
Cy Stein

Cy Aaron Stein, M.D., Ph.D.

Medical Oncologist
Clinical Expertise
Research Focus
  • Prostate Cancer
Appointments
Professor, Department of Medical Oncology & Therapeutics Research

Clinical Teams

  • Genitourinary
The relief of human suffering and anxiety may be the most satisfying long-term thing a human being can do."
Specializing in prostate cancer, Dr. Stein is a sought-after expert whose authored hundreds of scholarly papers and several medical texts including Molecular Medicine. He also holds 11 patents. Yet his No. 1 advice to fellow physicians is, “Never think about yourself. It's only about the patient.”
 
Dr. Stein graduated from Brown University with his B.A. and earned his Ph.D. in chemistry from Stanford University. He earned his medical degree at New York's Albert Einstein College of Medicine, completed his internship and residency at New York Hospital-Cornell University and followed with a five-year assignment at the National Cancer Institute in Bethesda, Maryland. Returning to New York, he spent the next two decades establishing himself as a foremost physician and educator at Columbia University, Einstein, and the Montefiore Medical Center. He joined City of Hope in 2012.
 
Outside the office, Dr. Stein channels his creative energy into writing historical fiction. His novel, The Medicus Codex, is told from the perspective of a Judean physician in ancient Rome. It is available on Amazon.

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Liu W, Bulgaru A, Haigentz M, Stein CA, Perez-Soler R, and Mani S.  The bcl- 2-family of protein ligands as cancer drugs:  The next generation of therapuetics.  Curr. Med. Chem.-Anti-Cancer Agents,  2003 (3), 217-223.

Nichols G. and Stein CA. "Modulation of the activity of bcl-2 in Waldenstrom's Macroglobulinemia using antisense oligonucleotides" Semin. Oncol. 2003, (30) 297-299.

Wang L, Prakash R, Stein CA, Koehn R, and Ruffner D.  "Progress in the Delivery of Therapeutic Oligonucleotides: Organ/cellular Distribution and Targeted Delivery of Oligonucleotides In Vivo", Antisense and Nucleic Acid Drug Development, 2003 (13) 169-189.

Cho-Chung Y, Gewirtz A, and Stein CA. (eds).  Therapeutic Oligonucleotides.  Ann. NY Acad Sci., 2003 (1002).

Stein CA, Dias N, Benimetskaya L, Jepsen J, Lai J and Raffo A. "LY900003 (Isis 3521) and G3139 (Genasense; Oblimersen)-Phosphorothioate Antisense Oligonucleotides With Pleotropic Mechanisms of Action." Nucleic Acid Therapeutics in Cancer, A. Gewirtz, ed., 2004, 171-191.

Stein CA, Mani S, and Benimetskaya L. "Combinations of Chemotherapy with Antisense Approaches Against bcl-2", in Combination Cancer Therapy: Modulators and Potentiators, G., Schwartz, ed., Humana Press, 2005, p. 207-228

Stein CA, Benimetskaya L and Mani S. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 7th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2005, p. 2891-2898.

Stein CA and Rossi J. "A Critical Assessment of the Potential of Short Interfering RNA Therapeutics', Drug Discovery Today: Technologies, 2005, www.drugdiscoverytoday.com; http://www.sciencedirect.com (2) 27-31.

Cho-Chung Y, Gewirtz A, and Stein CA. (eds).  Therapeutic Oligonucleotides-Transcriptonal and Translational Strategies for Silencing Gene Expression.  Ann. NY Acad Sci., 2005 (1058)

Benimetskaya L, Lai J, Khvorova A, Wu S, Miller P and Stein CA.  "Induction of Apoptosis by G3139 in Melanoma Cells", Ann. NY Acad. Sci, 2005 (1058) 235-245.

Stein CA, Benimetskaya L, and Mani S.  "Antisense Strategies for Oncogene Inactivation", Semin. Oncol. 2005, (32) 563-572.

Kornblum N, Ayyanar K, Benimetskaya L, Richardson P, Iacobelli M, and Stein CA. "Defibrotide, a Polydisperse Mixture of Single-Stranded Phosphodiester Oligonucleotides with Life-Saving Activity in Severe Hepatic Veno-Occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action", Oligonucleotides, 2006 (16), 105-114.

Stein CA. "The Genasense 'Learning Curve'", Letter to the Editor, Nature Biotechnology, 2007 (25) 972-973.

Stein CA.  "Genasense: It Ain't Over Till the Fat Lady Sings", Editorial, Oligonucleotides, 2007 (17) 345-348.

Stein CA. Kornblum N, Lai J, and Benimetskaya L. "Genasense (G3139): An antisense Bcl-2 oligodeoxyribonucleotide with substantial clinical activity and a complex mechanism of action".  In Therapeutic Oligonucleotides, J. Kurreck, ed., Biomolecular Science, Royal Society of Chemistry, 2008, p. 23-42.

Stein CA., Benimetskaya L, Kornblum N, and Mani S. "Antisense Agents", in Principles and Practice of Oncology, 8th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2008.

Stein CA and Colombini M.  "Specific VDAC Inhibitors:  Phosphorothioate Oligonucleotides" J. Bioenerg. Biomemb., 2008, 40:157-162.

Stein CA, Hoehn B and Rossi J.  "Oligonucleotide Therapeutics"  In Principles of Anticancer Drug Development, E. Garrett-Mayer, et al., eds. Springer Press, 2011, p. 565-587.

Stein CA and Soifer H. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 9th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2011.

Soifer H, Koch T, Hansen B, Hoeg A, Oerum H and Stein CA. "Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides" in M. Kaufmann and C. Klinger, eds., Functional Genomics:  Methods and Protocols: Methods in Molecular Biology, 815:333-346 Springer Press, 2011.

Stein CA and Goel S.  "Therapeutic Oligonucleotides-The Road Not Taken", invited commentary in Clinical Cancer Research, 2011, 17:6369-6372.

Twardowski P and Stein CA. "Beyond the Abstract-Direct regulation of androgen receptor activity in prostate cancer cells by potent CYP17 inhibitors". UroToday.com, July 2, 2012

Hu J, Hsu J, Bergerot P, Yuh B, Stein CA and Pal S.  "Preoperative therapy for localized prostate cancer: A comprehensive overview", Maturitas, 2013, 74:3-9.

Pal S, Stein CA, and Sartor O. "Enzalutamide for the treatment of prostate cancer," Expert Opinion in Pharmacotherapy, 2013, (14), 679-685

Eroglu Z, Stein CA, Pal S.  "Targeting angiopoietin-2 signaling in cancer therapy, Expert Opinion in Investigational Drugs, 2013, (22), 813-825.
 

In The News